1-12 of 12
Lüder-Hinrich Meyer, MD
Close
Sort by
Journal Articles

Characterization of Mechanisms of Acquired Venetoclax-Insensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Alexandra Niedermayer, MSc, Stefanie Enzenmüller, PhD, Eugen Tausch, Stephan Stilgenbauer, MD, Felix Seyfried, MD, Klaus-Michael Debatin, MD, Lüder Hinrich Meyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3954.
https://doi.org/10.1182/blood-2019-126582
Published: 2019
Journal Articles

Biomarker Profile for Prediction of Patient Response to Smac Mimetic Monotherapy in Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia

Julia Zinngrebe, MD, Ferdinand Schlichtig, Malcolm Meyer, Johann M. Kraus, Elena Boldrin, PhD, Hans A. Kestler, Lüder Hinrich Meyer, MD, Pamela Fischer-Posovszky, Klaus-Michael Debatin, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2082.
https://doi.org/10.1182/blood-2019-130967
Published: 2019
Journal Articles

Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2

Daniela Steinbrecher, PhD, Felix Seyfried, MD, Eugen Tausch, Johannes Bloehdorn, MD, Billy Michael Chelliah Jebaraj, PhD, Klaus-Michael Debatin, MD, Lüder Hinrich Meyer, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD, Christof Schneider, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1507.
https://doi.org/10.1182/blood-2019-127931
Published: 2019
Journal Articles

Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option

Daniela Steinbrecher, MSc, Felix Seyfried, Johannes Bloehdorn, MD, Billy Michael Chelliah Jebaraj, PhD, Lüder Hinrich Meyer, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, Christof Schneider, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1580.
https://doi.org/10.1182/blood-2018-99-115845
Published: 2018
Journal Articles

Synergistic Activity of the MCL-1-Specific Inhibitor S63845 with Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia

Felix Seyfried, Felix Stirnweiß, Stefan Köhrer, MD, Klaus-Michael Debatin, MD, Lüder Hinrich Meyer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1416.
https://doi.org/10.1182/blood-2018-99-117139
Published: 2018
Journal Articles

FOXO1 Is Involved in the Regulation of B-Cell Precursor Acute Lymphoblastic Leukemia Survival and Serves As a Novel Target for Directed Therapy

Salih Demir, MSc, Fan Wang, Franziska Gehringer, Clarissa Weitzer, Klaus-Michael Debatin, MD PhD, Thomas Wirth, Prof. Dr., Lüder Hinrich Meyer, MD, Alexey Ushmorov, Dr.
Journal: Blood
Blood (2016) 128 (22): 4020.
https://doi.org/10.1182/blood.V128.22.4020.4020
Published: 2016
Journal Articles

Lysosomal Cell Death and Apoptosis Crosstalk - Synergistic Role in Bcl-2 Inhibitor (ABT-263) Mediated Cell Death in B-Cell Precursor Acute Lymphoblastic Leukemia

Stefanie Enzenmüller, PhD, Qian Sun, PhD, Klaus-Michael Debatin, MD PhD, Lüder-Hinrich Meyer, MD
Journal: Blood
Blood (2016) 128 (22): 1584.
https://doi.org/10.1182/blood.V128.22.1584.1584
Published: 2016
Journal Articles

Anti-Leukemia Activity of the Selective BCL-2 Inhibitor ABT-199 in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By MCL-1/BCL-2 Expression Serving As Biomarker for Treatment Response

Felix Seyfried, MD, Salih Demir, MSc, Rebecca Hörl, Stefan Köhrer, Annika Scheffold, Stephan Stilgenbauer, Klaus-Michael Debatin, MD PhD, Lüder Hinrich Meyer, MD
Journal: Blood
Blood (2016) 128 (22): 1081.
https://doi.org/10.1182/blood.V128.22.1081.1081
Published: 2016
Journal Articles

TET1 Promotes Leukemic Growth in T-ALL Via Maintenance of 5-Hydroxymethylation Marks and Can be Antagonized By the PARP Inhibitor Olaparib

Deniz Sahin, M.Sc, Shiva Bamezai, PhD, Fabio Ciccarone, PhD, Elena Fischbein, MSc, Fabian Mohr, PhD, Medhanie A. Mulaw, Jun.-Prof. Dr., Alex Pulikkottil Jose, M.Sc, Paola Caiafa, MD, Lüder-Hinrich Meyer, MD, Klaus-Michael Debatin, Prof. Dr., Geertruy te Kronnie, PhD, Konstanze Döhner, Hartmut Döhner, Prof. Dr., Michaela Feuring-Buske, PD Dr., Christian Buske, Vijay P.S. Rawat, PhD
Journal: Blood
Blood (2016) 128 (22): 737.
https://doi.org/10.1182/blood.V128.22.737.737
Published: 2016
Journal Articles

Targeting Mutant p53 in Pediatric Acute Lymphoblastic Leukemia

Salih Demir, MSc, Galina Selivanova, PhD, Eugen Tausch, MD, Lisa Wiesmüller, PhD, Stephan Stilgenbauer, MDPhD, Geertruy Te Kronnie, PhD, Klaus-Michael Debatin, MDPhD, Lüder Hinrich Meyer, MD
Journal: Blood
Blood (2015) 126 (23): 903.
https://doi.org/10.1182/blood.V126.23.903.903
Published: 2015
Journal Articles

Immunoglobulin Heavy Chain (IgH) Knockout Inhibits Proliferation of Pre-BCR + B-Cell Acute Lymphoblastic Leukemia (B-ALL) Via a FOXO1 and MYC Dependent Mechanism

Stefan Koehrer, MD, Ondrej Havranek, MDPhD, R Eric Davis, MD, Felix Seyfried, MD, Greg Coffey, PhD, Ekaterina Kim, MS, Nathalie Y. Rosin, PhD, Elisa ten Hacken, PhD, Ulrich Jäger, MD, Katrina Vanura, PhD, Susan O'Brien, MD, Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Dipanjan Ghosh, PhD, Zhiqiang Wang, Lüder Hinrich Meyer, MD, Hassan Jumaa, PhD, Jan A. Burger, MDPhD
Journal: Blood
Blood (2014) 124 (21): 287.
https://doi.org/10.1182/blood.V124.21.287.287
Published: 2014
Journal Articles

Effective in Vivo Targeting of BCP-ALL in a NOD/SCID/huALL Mouse Model By CD70 Directed Immunotherapy

Qian Sun, PhD, Chiara Borga, PhD, Geertruy te Kronnie, PhD, Klaus-Michael Debatin, MDPhD, Lüder Hinrich Meyer, MD
Journal: Blood
Blood (2014) 124 (21): 970.
https://doi.org/10.1182/blood.V124.21.970.970
Published: 2014